Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edArlington (VA)APA2013
   Google Scholar
• National Institute of Mental HealthSchizophrenia2016 Available from: http://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtmlAccessed June 19, 2018
   Google Scholar
• CloutierMAigbogunMSGuerinAThe economic burden of schizophrenia in the United States in 2013J Clin Psychiatry201677676477127135986
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-makingExpert Opin Pharmacother200910121917192819558339
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl156
   PubMed Web of Science ®Google Scholar
• BrissosSMolodynskiADiasVVFigueiraMLThe importance of measuring psychosocial functioning in schizophreniaAnn Gen Psychiatry2011101821702932
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia2nd ed2010 Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdfAccessed June 19, 2018
   Google Scholar
• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcevoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• HaroJMSuarezDNovickDBrownJUsallJNaberDThree-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies resultsEur Neuropsychopharmacol200717423524417137759
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWStaufferVReasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesCurr Med Res Opin201026102403241020812791
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• CorrellCUSkubanAOuyangJEfficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trialAm J Psychiatry2015172987088025882325
   PubMed Web of Science ®Google Scholar
• KaneJMSkubanAOuyangJA multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophr Res20151641–312713525682550
   PubMed Web of Science ®Google Scholar
• KaneJMSkubanAHobartMOverview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophreniaSchizophr Res20161741–3939827188270
   PubMed Web of Science ®Google Scholar
• FleischhackerWWHobartMOuyangJEfficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomised, double-blind, placebo-controlled studyInt J Neuropsychopharmacol2017201112127566723
   PubMed Web of Science ®Google Scholar
• NeumannPJMethods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatmentJ Clin Psychiatry199960Suppl 3915
   Google Scholar
• CitromeLKamatSASapinCCost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United StatesJ Med Econ201417856757624758296
   PubMedGoogle Scholar
• DurgamSEarleyWLiRLong-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trialSchizophr Res20161762–326427127427558
   PubMed Web of Science ®Google Scholar
• TandonRCucchiaroJPhillipsDA double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophreniaJ Psychopharmacol2016301697726645209
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellencePsychosis and schizophrenia overview2018 Available from: https://pathways.nice.org.uk/pathways/psychosis-and-schizophreniaAccessed June 19, 2018
   Google Scholar
• CitromeLBrexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract201569997899726250067
   PubMed Web of Science ®Google Scholar
• Rexulti [package insert]TokyoOtsuka Pharmaceutical2016
   Google Scholar
• Latuda [package insert]Marlborough (MA)Sunovion Pharmaceuticals2013
   Google Scholar
• CitromeLLurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clin Schizophr Relat Psychoses201262768522776634
   PubMedGoogle Scholar
• US Bureau of Labor StatisticsConsumer price index: medical care Available from: https://data.bls.gov/cgi-bin/surveymost?cuAccessed June 19, 2018
   Google Scholar
• LenertLASturleyAPRapaportMHPublic preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scoresSchizophr Res200471115516515374583
   PubMed Web of Science ®Google Scholar
• FuriakNMAscher-SvanumHKleinRWCost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision modelCurr Med Res Opin201127471373021265593
   PubMed Web of Science ®Google Scholar
• LevyARChristensenTLJohnsonJAUtility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United KingdomHealth Qual Life Outcomes200867318823555
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFuriakNMLawsonAHCost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United StatesJ Med Econ201215353154722304338
   PubMedGoogle Scholar
• TreurMBacaEBobesJThe cost-effectiveness of paliperidone extended release in SpainJ Med Econ201215Suppl 1263423016569
   PubMedGoogle Scholar
• Costco [homepage] Available from: https://www.costco.comAccessed June 19, 2018
   Google Scholar
• MacewanJPSeaburySAigbogunMSPharmaceutical innovation in the treatment of schizophrenia and mental disorders compared with other diseasesInnov Clin Neurosci2016137–8172527672484
   PubMedGoogle Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry200418434635115056580
   PubMed Web of Science ®Google Scholar
• Ng-MakDChuangCCBakerTLiJRajagopalanKLoebelALurasidone versus brexpiprazole in adult schizophrenia: cost-effectiveness analysisPoster presented at: 29th Annual US Psychiatric and Mental Health CongressOctober 21–24San Antonio, TX
   Google Scholar
• O’DayKRajagopalanKMeyerKPikalovALoebelALong-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the USClinicoecon Outcomes Res2013545947024049452
   PubMedGoogle Scholar
• RajagopalanKHassanMO’DayKMeyerKGrossmanFCost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial dataJ Med Econ201316795196123701260
   PubMedGoogle Scholar
• CsernanskyJGMahmoudRBrennerRA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophreniaN Engl J Med20023461162211777998
   PubMed Web of Science ®Google Scholar
• LoebelASilvaRGoldmanRLurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled studyJ Clin Psychiatry201677121672168027454547
   PubMed Web of Science ®Google Scholar
• CitromeLSchizophrenia relapse, patient considerations, and potential role of lurasidonePatient Prefer Adherence2016101529153727563237
   PubMed Web of Science ®Google Scholar
• MeltzerDPerspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophreniaJ Clin Psychiatry199960Suppl 333237
   Google Scholar
• BeasleyCMSuttonVKHamiltonSHA double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapseJ Clin Psychopharmacol200323658259414624189
   PubMed Web of Science ®Google Scholar
• PeuskensJTrivediJMalyarovSPrevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patientsPsychiatry (Edgmont)20074113450
   PubMedGoogle Scholar
• AratoMO’ConnorRMeltzerHYA 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) studyInt Clin Psychopharmacol200217520721512177583
   PubMed Web of Science ®Google Scholar
• PigottTACarsonWHSahaARAripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week studyJ Clin Psychiatry20036491048105614628980
   PubMed Web of Science ®Google Scholar
• Vraylar (cariprazine) [summary review]2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000SumR.pdfAccessed June 19, 2018
   Google Scholar
• DurgamSStaraceALiDAn evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trialSchizophr Res20141522–345045724412468
   PubMed Web of Science ®Google Scholar
• Zyprexa [package insert]IndianapolisLilly USA2014
   Google Scholar
• Risperdal [package insert]Titusville (NJ)Janssen Pharmaceutical2009
   Google Scholar
• Seroquel [package insert]Wilmington (DE)AstraZeneca Pharmaceuticals2009
   Google Scholar
• Geodon [package insert]New YorkPfizer2009
   Google Scholar
• Abilify [package insert]TokyoOtsuka Pharmaceutical2012
   Google Scholar
• Agency for Healthcare Research and QualityHCUPnet: Healthcare Cost and Utilization Project Nationwide Inpatient Sample2013 Available from: http://hcupnet.ahrq.govAccessed June 19, 2018
   Google Scholar
• ParkTKuntzKMCost-effectiveness of second-generation antipsychotics for the treatment of schizophreniaValue Health201417431031924968989
   PubMed Web of Science ®Google Scholar
• Truven Health AnalyticsMicromedex 2.0: introduction to Red Book onlineAccessed June 19, 2018
   Google Scholar